Brief: Enanta Pharmaceuticals Inc - Phase 1 Data Presented Continue To Highlight EDP-235'S Promising Overall Safety, Tolerability, Pharmacokinetic Profile
14/03/2023 11:13
March 14 (Reuters) - Enanta Pharmaceuticals Inc ENTA.O :
* ENANTA PHARMACEUTICALS INC - PHASE 1 DATA PRESENTED
CONTINUE TO
HIGHLIGHT EDP-235'S PROMISING OVERALL SAFETY, TOLERABILITY,
PHARMACOKINETIC PROFILE
* ENANTA PHARMACEUTICALS - PRECLINICAL ANIMAL DATA INDICATE
POTENTIAL FOR EDP-235 TO REDUCE HOUSEHOLD TRANSMISSION, TO
MINIMIZE SARS-COV-2 REBOUND
Source text for Eikon: ID:nBw5MYqGCa
Further company coverage: ENTA.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Enanta Pharmaceuticals
See all newsEnanta Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Enanta Pharmaceuticals Q3 revenue misses estimates, hurt by lower royalties
Enanta Pharmaceuticals Inc expected to post a loss of 51 cents a share - Earnings Preview
Enanta Pharma Q2 loss narrows on higher AbbVie royalties, lower costs
Enanta Pharmaceuticals Q1 revenue beats estimates